Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· June 24, 2026

Paychex outlines FY 2027 outlook with 5%-6% revenue growth and ~44% adjusted operating margin

View original at seekingalpha.com
“borrowings were "approximately $4.6 billion"”
Verbatim excerpt from the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FY2027 adjusted operating income margin is expected to be approximately 44%, effective tax rate approximately 24%, adjusted diluted EPS growth 7% to 9%, and Q1 adjusted operating margin 41% to 42%.

    60% confidence
  • Paychex exited fiscal 2026 with strong momentum, citing double-digit revenue and earnings growth in the fourth quarter and full year, with accelerating organic revenue growth each quarter.

    60% confidence
  • WISE is Paychex's AI-powered intelligence engine powering approximately 600 AI features and agents, drawing on more than 26 trillion data points.

    60% confidence
  • Q4 total revenue increased 12% over the prior year to $1.6 billion, with Management Solutions revenue up 14% to $1.2 billion and PEO and Insurance Solutions revenue up 9% to $370 million.

    60% confidence
  • Paychex exceeded its fiscal 2026 synergy targets from the Paycor acquisition, with over 50 basis points of revenue-growth contribution and over $100 million in cost synergies, and is winning larger deals than anticipated.

    60% confidence
  • Paychex returned $2.2 billion to shareholders through $1.6 billion in cash dividends and $600 million in share repurchases, and reduced leverage by 0.5 turn, including repayment of the initial $400 million Oasis acquisition debt tranche.

    60% confidence
  • Interest on funds held for clients is expected to be in the range of $195 million to $205 million, declining due to prior rate cuts and lapping one-time portfolio repositioning gains, assuming no further Fed funds rate changes.

    60% confidence
  • Paychex's client base is relatively flat, with growth driven by an increase in revenue per client.

    60% confidence
  • Health care cost inflation is unsustainable for small and mid-sized businesses, acting as a double-edged sword that pressures affordability while supporting PEO demand.

    60% confidence
  • Q4 interest on funds held for clients grew 15% to $52 million; operating income margin increased approximately 750 basis points to 37.7%; adjusted operating income margin increased approximately 170 basis points to 42.1%; diluted EPS increased 43% to $1.17; adjusted diluted EPS increased 11% to $1.32.

    60% confidence
  • Fiscal 2027 total revenue growth is guided in the range of 5% to 6%, Management Solutions revenue growth 5% to 6%, and PEO and Insurance Solutions revenue growth 6% to 7%.

    60% confidence
  • Midterm organic growth is typically 7% to 8%, with M&A adding 1% to 2%, and no acquisition on the scale of the Paycor deal is expected near-term.

    60% confidence
  • Paychex is already generating AI revenue, with about 10,000 customers in a timekeeping AI soft launch that is cutting errors by roughly 70% upfront.

    60% confidence
  • PEO strength includes record worksite employee retention, while the insurance agency continues to be a drag though some positive trends are emerging.

    60% confidence
  • Fiscal 2026 total revenue increased 17% over the prior year to $6.5 billion, operating cash flow increased 35% to $2.6 billion, and free cash flow increased 36% to $2.3 billion.

    60% confidence
  • PEO remains a key growth driver, with worksite employee growth outpacing the industry at high single-digit rates in the quarter and full year.

    60% confidence
  • Client retention for 100-plus employee accounts is the highest it has been in Gibson's 13 years at the company, and Paychex will not do irrational things to boost client counts.

    60% confidence
  • Asked whether Paychex could size how much of the apparent Paycor deceleration is revenue shifting rather than true slowdown.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com